Haschka, Manuel D <br/><br/>
MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment.  [electronic resource] 

 -  Cell death and differentiation  08 2020 
 - 2297-2312 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5403 
<br/><br/><label>Standard No.: </label>10.1038/s41418-020-0503-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimitotic Agents--pharmacology<br/>Caspases--metabolism<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Enzyme Activation--drug effects<br/>Humans<br/>Membrane Proteins--metabolism<br/>Myeloid Cell Leukemia Sequence 1 Protein--metabolism<br/>Protein Binding--drug effects<br/>Protein Stability--drug effects<br/>Proteolysis--drug effects<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Ubiquitin-Protein Ligases--metabolism<br/>Ubiquitination--drug effects